A groundbreaking test developed by UNC researchers can now help doctors identify which high-risk breast cancer patients can safely skip chemotherapy, sparing them from grueling side effects without compromising their survival outcomes.

The Prosigna test represents a significant leap forward in personalised cancer care, allowing physicians to distinguish between patients who truly need chemotherapy and those who can achieve excellent results with hormone therapy alone. This precision approach means fewer patients enduring the exhausting and sometimes lasting effects of chemotherapy, while ensuring those who need it still receive optimal treatment. Read the full story →

Today's takeaway: Smart testing is helping doctors give cancer patients the right treatment the first time—maximising hope and minimising unnecessary suffering.